380 related articles for article (PubMed ID: 30561762)
1. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
[TBL] [Abstract][Full Text] [Related]
3. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
4. Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study.
Pina A; Wolber R; McAlpine JN; Gilks B; Kwon JS
Int J Gynecol Cancer; 2018 Oct; 28(8):1624-1630. PubMed ID: 30095707
[TBL] [Abstract][Full Text] [Related]
5. Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications.
Doghri R; Houcine Y; Boujelbène N; Driss M; Charfi L; Abbes I; Mrad K; Sellami R
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):678-682. PubMed ID: 31567138
[TBL] [Abstract][Full Text] [Related]
6. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
[TBL] [Abstract][Full Text] [Related]
8. Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma.
Gan Q; Crumley S; Broaddus RR
Int J Gynecol Pathol; 2019 Jan; 38(1):44-51. PubMed ID: 29210800
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
Han KH; Kim HS; Lee M; Chung HH; Song YS
Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
[TBL] [Abstract][Full Text] [Related]
11. Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients.
Kato MK; Yoshida H; Tanase Y; Uno M; Ishikawa M; Kato T
Pathol Oncol Res; 2021; 27():598550. PubMed ID: 34257552
[No Abstract] [Full Text] [Related]
12. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
[TBL] [Abstract][Full Text] [Related]
13. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
[TBL] [Abstract][Full Text] [Related]
14. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.
Nelson GS; Pink A; Lee S; Han G; Morris D; Ogilvie T; Duggan MA; Köbel M
Gynecol Oncol; 2013 Nov; 131(2):309-14. PubMed ID: 23938375
[TBL] [Abstract][Full Text] [Related]
15. Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma.
Vasan K; Satgunaseelan L; Anand S; Asher R; Selinger C; Low TH; Palme CE; Clark JR; Gupta R
Pathology; 2019 Dec; 51(7):688-695. PubMed ID: 31630878
[TBL] [Abstract][Full Text] [Related]
16. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.
Shuen AY; Lanni S; Panigrahi GB; Edwards M; Yu L; Campbell BB; Mandel A; Zhang C; Zhukova N; Alharbi M; Bernstein M; Bowers DC; Carroll S; Cole KA; Constantini S; Crooks B; Dvir R; Farah R; Hijiya N; George B; Laetsch TW; Larouche V; Lindhorst S; Luiten RC; Magimairajan V; Mason G; Mason W; Mordechai O; Mushtaq N; Nicholas G; Oren M; Palma L; Pedroza LA; Ramdas J; Samuel D; Wolfe Schneider K; Seeley A; Semotiuk K; Shamvil A; Sumerauer D; Toledano H; Tomboc P; Wierman M; Van Damme A; Lee YY; Zapotocky M; Bouffet E; Durno C; Aronson M; Gallinger S; Foulkes WD; Malkin D; Tabori U; Pearson CE
J Clin Oncol; 2019 Feb; 37(6):461-470. PubMed ID: 30608896
[TBL] [Abstract][Full Text] [Related]
17. Definitive radiotherapy for vaginal recurrence of early-stage endometrial cancer: survival outcomes and effect of mismatch repair status.
Alban G; Cheng T; Adleman J; Buzurovic I; Pretz J; Singer L; King M; Lee L
Int J Gynecol Cancer; 2021 Jul; 31(7):1007-1013. PubMed ID: 33858956
[TBL] [Abstract][Full Text] [Related]
18. Effect of Mismatch Repair Status on Outcome of Early-Stage Grade 1 to 2 Endometrial Cancer Treated With Vaginal Brachytherapy.
Russo AL; Lee LJ; Wo JY; Niemierko A; Park D; Alban G; King M; Philp L; Growdon WB; Oliva E; Spriggs DR; Yeku OO
Am J Clin Oncol; 2022 Jan; 45(1):36-39. PubMed ID: 34817442
[TBL] [Abstract][Full Text] [Related]
19. The immunohistochemistry signature of mismatch repair (MMR) proteins in a multiethnic Asian cohort with endometrial carcinoma.
Woo YL; Cheah PL; Shahruddin SI; Omar SZ; Arends M
Int J Gynecol Pathol; 2014 Nov; 33(6):554-9. PubMed ID: 25272293
[TBL] [Abstract][Full Text] [Related]
20. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers.
Kato M; Takano M; Miyamoto M; Sasaki N; Goto T; Tsuda H; Furuya K
J Gynecol Oncol; 2015 Jan; 26(1):40-5. PubMed ID: 25310854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
